Page 129 - ESHRE2019

Clinical trials with hESC-derivatives Type 1 diabetes
PEC-DirectTM- VC02 May 2017
• Open device allows direct vascularization similar to a natural islet
• Immunosuppressive medication is needed
Clinical trials with hESC-derivatives Spinal cord injury
AST-OPC1, oligodendrocyte progenitor population derived from hESC
Phase 1: 5 patients (2M cells injection 7-14 days post-injury) 60 days of immunosupression
no serious adverse events or rejection evidence 4 / 5 p a t i e n t s r e d u c e d s p i n a l c o r d c a v i t a t i o n ( M RI )
Pha se 1/ 2a : 35 patients (2/10/10M cells injection 14-30 days post-injury) 15 years of monitorization
January 2019
• Improved Motor Function
• At least one-level: 95% (21/22 patients) • Two or more levels 32% (7/22 patients)
• Cell Engraftment – 95% (21/22)
• Positive Safety Profile – no serious adverse events (SAEs)
PCC Stem Cells - ESHRE Vienna 2019
124
PRECONGRESS COURSE 13 I VIENNA, AUSTRIA – 23 JUNE 2019 127